| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Across the last three months, Rapport Therapeutics, Inc.'s insiders have reduced their positions by a net 2,210 shares worth roughly $93K. In the past 30 days, 0 insiders bought and 1 sold.
Not all activity pointed one way: 1 insider sold in the same window, though they still hold shares. Classified under Biotechnology (Health Care sector), RAPP's insider flows are most useful compared with peers in the same group.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 6.71M | $329.22M | - | |
| CEO | 537.6K | $26.38M | -2,210 | |
| Other | 395.6K | $19.41M | - | |
| Other | 299.8K | $14.71M | - | |
| COO | 105.4K | $5.17M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 16, 2025 | Bredt David | Chief Scientific Officer | Sell | 8,500 | $11.00 | $93,522.10 | -1.9% | +120.8% | +243.7% | |
| May 15, 2025 | Bredt David | Chief Scientific Officer | Sell | 8,500 | $9.56 | $81,261.70 | -1.8% | +59.9% | +280.0% | |
| Apr 15, 2025 | Bredt David | Chief Scientific Officer | Sell | 8,500 | $9.57 | $81,310.15 | -1.8% | +52.4% | +255.9% | |
| Mar 14, 2025 | Bredt David | Chief Scientific Officer | Sell | 8,500 | $10.85 | $92,205.45 | -1.8% | +6.0% | +164.9% | |
| Mar 13, 2025 | Ignelzi Troy A. | Chief Financial Officer | Buy | 10,000 | $10.10 | $100,988.00 | +101.0% | +20.8% | +177.8% | |
| Mar 12, 2025 | Young Wendy B. | Director | Buy | 6,000 | $10.21 | $61,249.80 | New | +31.5% | +186.4% | |
| Jul 1, 2024 | Healy James | Director | Buy | 44,032 | $24.52 | $1,079,575.36 | +12.7% | -19.5% | -55.5% | |
| Jun 10, 2024 | Healy James | Director | Buy | 558,824 | $17.00 | $9,500,008.00 | +40.1% | -24.9% | -49.8% |